RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion.
Steroid receptor coactivator 3 is a key modulator of regulatory T cell-mediated tumor evasion.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
类固醇受体共激活因子3(SRC-3)在调节性T细胞(Tregs)和B细胞中表达最强,提示其在Treg功能调节中发挥重要作用。利用侵袭性E0771小鼠乳腺癌细胞系同基因免疫健全小鼠模型,我们观察到,在一种基因工程他莫昔芬诱导型Treg细胞特异性SRC-3敲除(KO)雌性小鼠中,乳腺肿瘤被“永久性根除”,且该小鼠不具有系统性自身免疫病理表型。在前列腺癌同基因模型中也观察到类似的肿瘤根除现象。随后向这些小鼠注射额外的E0771癌细胞,显示其持续抵抗肿瘤发生,且无需他莫昔芬诱导以产生额外的SRC-3 KO Tregs。SRC-3 KO Tregs高度增殖,并通过激活趋化因子(C-C基序)配体(Ccl)19/Ccl21/趋化因子(C-C基序)受体(Ccr)7信号轴优先浸润至乳腺肿瘤,通过增强干扰素-γ/C-X-C基序趋化因子配体(Cxcl)9信号轴来促进效应T细胞和NK 细胞的进入和功能,从而产生抗肿瘤免疫。SRC-3 KO Tregs还通过阻断WT Tregs的免疫抑制功能表现出主导效应。
重要的是,将SRC-3 KO Tregs单次过继转移至野生型E0771荷瘤小鼠中,可通过产生具有持久效果的强效抗肿瘤免疫完全消除已建立的乳腺肿瘤,从而防止肿瘤复发。
因此,使用SRC-3缺失的Tregs治疗代表了一种完全阻断肿瘤生长和复发的方法,且不会产生通常伴随免疫检查点调节剂的自身免疫副作用。
Steroid receptor coactivator 3 (SRC-3) is most strongly expressed in regulatory T cells (Tregs) and B cells, suggesting that it plays an important role in the regulation of Treg function. Using an aggressive E0771 mouse breast cell line syngeneic immune-intact murine model, we observed that breast tumors were "permanently eradicated" in a genetically engineered tamoxifen-inducible Treg-cell-specific SRC-3 knockout (KO) female mouse that does not possess a systemic autoimmune pathological phenotype. A similar eradication of tumor was noted in a syngeneic model of prostate cancer.
A subsequent injection of additional E0771 cancer cells into these mice showed continued resistance to tumor development without the need for tamoxifen induction to produce additional SRC-3 KO Tregs.
SRC-3 KO Tregs were highly proliferative and preferentially infiltrated into breast tumors by activating the chemokine (C-C motif) ligand (Ccl) 19/Ccl21/chemokine (C-C motif) receptor (Ccr)7 signaling axis, generating antitumor immunity by enhancing the interferon-γ/C-X-C motif chemokine ligand (Cxcl) 9 signaling axis to facilitate the entrance and function of effector T cells and natural killer cells. SRC-3 KO Tregs also show a dominant effect by blocking the immune suppressive function of WT Tregs.
Importantly, a single adoptive transfer of SRC-3 KO Tregs into wild-type E0771 tumor-bearing mice can completely abolish preestablished breast tumors by generating potent antitumor immunity with a durable effect that prevents tumor reoccurrence.
Therefore, treatment with SRC-3-deleted Tregs represents an approach to completely block tumor growth and recurrence without the autoimmune side effects that typically accompany immune checkpoint modulators.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。